MSX-122 (C09-0967-488)

InformationMSX-122 is a novel small molecule and partialCXCR4antagonist (IC50~10 nM).TargetsCXCR4 ~10 nMIn vitroMSX-122 is also incapable of blocking the binding of 125I-labeled CXCL12 to CXCR4. MSX-122 appears to be insufficiently large to block all binding sites between CXCR4 and CXCL12. MSX-122 blocks certain CXCR4 functions via binding to the CXCL12-binding site and interfering with CXCR4/CXCL12-mediated signaling. MSX-122 can intervene in the Gαi-signaling pathway (cAMP modulation), but not the Gq-pathway (calcium flux).In vivoMSX-122 blocks bleomycin-induced lung fibrosis involving chemotaxis and homing of CXCR4-positive mesenchymal progenitor cells into the lungs. MSX-122 exhibits anti-inflammatory activity in a carrageenan-induced paw edema model. MSX-122 blocks lung metastasis of breast cancer and SCCHN, and liver metastasis of uveal melanoma in vivo.Cell Research(from reference)Cell lines：MDA-MB-231 cells Concentrations：1, 10, 100, and 1000 nM Incubation Time：15 mins. Specification: 0.98 Molecular Formula: C16H16N6 Molecular Weight: 292.34 PubChem CID: 11687907 Isomeric SMILES: C1=CN=C(N=C1)NCC2=CC=C(C=C2)CNC3=NC=CC=N3 Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/M413551-SCI_c9dab4aa28e5b69479688ec75a45a70d.pdf